Novavax, Inc.

NASDAQ:NVAX   3:59:57 PM EDT
53.83
+2.16 (+4.18%)
4:00:25 PM EDT: $53.87 +0.04 (+0.07%)
Products, Community

Novavax Says Filed Supplement To A New Drug Submission In Canada For Nuvaxovid Covid-19 Vaccine For Adolescents Aged 12 Through 17 - Statement

Published: 06/23/2022 12:33 GMT
Novavax, Inc. (NVAX) - Novavax - Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ Covid-19 Vaccine for Adolescents Aged 12 Through 17 - Statement.
Preliminary Safety Data From the Trial Showed the Vaccine to Be Generally Well-tolerated.
Nuvaxovid Achieved Its Primary Effectiveness Endpoint and Demonstrated 80% Clinical Efficacy.